269 related articles for article (PubMed ID: 11483834)
1. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.
Luce BR; Zangwill KM; Palmer CS; Mendelman PM; Yan L; Wolff MC; Cho I; Marcy SM; Iacuzio D; Belshe RB
Pediatrics; 2001 Aug; 108(2):E24. PubMed ID: 11483834
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.
Bridges CB; Thompson WW; Meltzer MI; Reeve GR; Talamonti WJ; Cox NJ; Lilac HA; Hall H; Klimov A; Fukuda K
JAMA; 2000 Oct; 284(13):1655-63. PubMed ID: 11015795
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department.
Hart RJ; Stevenson MD; Smith MJ; LaJoie AS; Cross K
JAMA Pediatr; 2018 Jan; 172(1):e173879. PubMed ID: 29114729
[TBL] [Abstract][Full Text] [Related]
4. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
Allsup S; Gosney M; Haycox A; Regan M
Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051
[TBL] [Abstract][Full Text] [Related]
5. Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus: results from a pilot study.
Pisu M; Meltzer MI; Hurwitz ES; Haber M
Pharmacoeconomics; 2005; 23(1):55-67. PubMed ID: 15693728
[TBL] [Abstract][Full Text] [Related]
6. Potential cost savings attributable to influenza vaccination of school-aged children.
White T; Lavoie S; Nettleman MD
Pediatrics; 1999 Jun; 103(6):e73. PubMed ID: 10353970
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness study on influenza prevention in Hong Kong.
Fitzner KA; Shortridge KF; McGhee SM; Hedley AJ
Health Policy; 2001 Jun; 56(3):215-34. PubMed ID: 11399347
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness analysis of elementary school-located vaccination against influenza--results from a randomized controlled trial.
Yoo BK; Humiston SG; Szilagyi PG; Schaffer SJ; Long C; Kolasa M
Vaccine; 2013 Apr; 31(17):2156-64. PubMed ID: 23499607
[TBL] [Abstract][Full Text] [Related]
11. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses.
Nichol KL; Mendelman P
Virus Res; 2004 Jul; 103(1-2):3-8. PubMed ID: 15163481
[TBL] [Abstract][Full Text] [Related]
12. Economic impact of influenza vaccination in preschool children.
Cohen GM; Nettleman MD
Pediatrics; 2000 Nov; 106(5):973-6. PubMed ID: 11061762
[TBL] [Abstract][Full Text] [Related]
13. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
14. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness analysis of Year 2 of an elementary school-located influenza vaccination program-Results from a randomized controlled trial.
Yoo BK; Humiston SG; Szilagyi PG; Schaffer SJ; Long C; Kolasa M
BMC Health Serv Res; 2015 Nov; 15():511. PubMed ID: 26573461
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of influenza vaccination of healthy children.
Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model.
Gerlier L; Lamotte M; Grenèche S; Lenne X; Carrat F; Weil-Olivier C; Damm O; Schwehm M; Eichner M
Appl Health Econ Health Policy; 2017 Apr; 15(2):261-276. PubMed ID: 27943165
[TBL] [Abstract][Full Text] [Related]
20. Prioritization of risk groups for influenza vaccination in resource limited settings - A case study from South Africa.
McMorrow ML; Tempia S; Walaza S; Treurnicht FK; Ramkrishna W; Azziz-Baumgartner E; Madhi SA; Cohen C
Vaccine; 2019 Jan; 37(1):25-33. PubMed ID: 30471956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
